SAN DIEGO--(BUSINESS WIRE)--March 8, 2006--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced positive results from a recently completed clinical study that evaluated ZEGERID(R) (omeprazole/sodium bicarbonate) Powder for Oral Suspension 40 mg/1680 mg, Nexium(R) (esomeprazole magnesium) delayed-release capsules 40 mg and Prevacid(R) (lansoprazole) delayed-release capsules 30 mg with regard to reducing the occurrence of nocturnal acid breakthrough (NAB) when given to patients with nocturnal symptoms of gastroesophageal reflux disease (GERD) on an empty stomach at bedtime.
